News

The FDA has responded to Vion pharmaceuticals’ (Vion) Special Protocol Assessment (SPA) request to evaluate the phase III randomised trial, HOVON AML 92, sponsored by the Dutch-Belgian Cooperative

Basilea Pharmaceutica has reported that the FDA has issued to the sponsor, Johnson & Johnson Pharmaceutical Research and Development (Johnson & Johnson PRD), a Complete Response Letter on

Advaxis has reported the results of phase I trial of ADXS11-001, the company’s lead vaccine candidate. The study showed 36 month survival in two of the 13 evaluable

The American Diabetes Association (ADA) has reported that its new clinical practice recommendations call for the addition of A1C test as a means of diagnosing diabetes and identifying

Ranbaxy Laboratories (Ranbaxy) and HNG Chembio Pharmacy (HNG) have reported the transfer of Ranbaxy group’s entire shareholding in Ranbaxy Guangzhou China (RGCL) to HNG Chembio Pharmacy. RGCL was

Alnylam Pharmaceuticals (Alnylam) and collaborators from the David Koch Institute for Integrative Research at the Massachusetts Institute of Technology (MIT) have published new data in the journal Proceedings

Biostar Pharmaceuticals (Biostar) has completed preparation to launch Xin Aoxing Oleanolic Acid capsules in Beijing and Shanghai in early January 2010. The capsules are meant for the treatment

Kalgene Pharmaceuticals (Kalgene) has signed a commercial agreement to have Affomix utilise its Y2HExpress technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer. As

The US Patent & Trademark Office (USPTO) has granted reissue patent RE41,065 to OSI Pharmaceuticals (OSI) replacing Tarceva’s (erlotinib) composition of matter patent (formerly No.5,747,498). The company had